Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/IIa Gene Transfer Clinical Trial for LGMD2E (β-sarcoglycan Deficiency) Using scAAVrh74.MHCK7.hSGCB Administered by Systemic Perfusion

Trial Profile

Phase I/IIa Gene Transfer Clinical Trial for LGMD2E (β-sarcoglycan Deficiency) Using scAAVrh74.MHCK7.hSGCB Administered by Systemic Perfusion

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2018

At a glance

  • Drugs MYO 101 (Primary)
  • Indications Limb girdle muscular dystrophies
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Nov 2018 According to a Myonexus Therapeutics media release, the first patient in cohort 1 of this trial was dosed earlier in October and all patients in cohort 1 are expected to be dosed in 2018, with data expected by early 2019.
    • 31 Aug 2018 Status changed from planning to recruiting.
    • 16 May 2018 According to a Myonexus Therapeutics media release, the company is planning to start this trial later in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top